Product Description
Mechanisms of Action: RR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Brain Cancer
Phase 2: Lymphocytic Chronic B-Cell Leukemia|Non-Small-Cell Lung Cancer|Lymphoma, B-Cell|Glioma|Chronic Lymphoid Leukemia|Melanoma|Brain Cancer|Breast Cancer|Multiple Myeloma|Lymphoma, Non-Hodgkin|Adenocarcinoma|Gliosarcoma|Glioblastoma|Brain Stem Cancer|Renal Cell Carcinoma
Phase 1: Glioma|Squamous Cell Carcinoma|Laryngeal Cancer|Breast Cancer|Oligodendroglioma|Glioblastoma|Hypopharyngeal Cancer|Prostate Cancer|Head and Neck Cancer|Oropharyngeal Cancer|Astrocytoma|Non-Small-Cell Lung Cancer|Lymphoma|Bronchogenic Carcinoma|Colorectal Cancer|Intestinal Cancer|Myeloproliferative Disorders|Breast Diseases|Multiple Myeloma|Rectal Diseases|Myelodysplastic-Myeloproliferative Diseases|Prostatic Diseases|Lung Cancer|Intestinal Diseases|Leukemia, Plasma Cell|Plasmacytoma|Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
A6701QIBA | N/A |
Unknown status |
Prostate Cancer |
2022-12-01 |
|
NCI-2009-01092 | P2 |
Completed |
Glioblastoma|Gliosarcoma |
2011-02-16 |
|
NCI-2012-01829 | P2 |
Completed |
Glioma |
2010-04-01 |
|
PCYC-0222 | P2 |
Terminated |
Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia |
2010-02-01 |